Achieve Life Sciences to Present at H.C. Wainwright BIOCONNECT Virtual Conference

Rhea-AI Summary

Achieve Life Sciences (Nasdaq: ACHV), a clinical-stage pharmaceutical company focused on cytisinicline for smoking cessation, announced that CEO John Bencich will present at the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022. The presentation is scheduled for January 10 at 7:00 am ET. Investors can register for the conference online. Cytisinicline is an investigational drug aimed at treating nicotine addiction, showing potential in reducing withdrawal symptoms and cravings. It is not yet FDA approved.

SEATTLE, Wash, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that John Bencich, Chief Executive Officer, will give a presentation at the H.C. Wainwright BIOCONNECT Virtual Conference. The conference is taking place virtually from January 10 - 13, 2022. Details for access to the presentation are as follows: 

H.C. Wainwright BIOCONNECT Virtual Conference:
Date: January 10, 2022
Time: 7:00 am ET
Investors can register for the conference HERE.

Following the conference, a webcast replay of the presentation will be available on the Investor section of the company’s website, Achieve Life Sciences.

About Achieve and Cytisinicline 
Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually.^1,2 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.² Achieve’s focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.

Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.

Cytisinicline is an investigational product candidate being developed for treatment of nicotine addiction and has not been approved by the Food and Drug Administration for any indication in the United States. For more information on cytisinicline and Achieve, visit www.achievelifesciences.com.

Investor Relations Contact
Rich Cockrell
achv@cg.capital
(404) 736-3838

Media Contact
Glenn Silver
Glenn.Silver@Finnpartners.com
(646) 871-8485

References 
¹ World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017. 
² U.S. Department of Health and Human Services. The Health Consequences of Smoking – 50 Years of Progress. A Report of the Surgeon General, 2014.  

FAQ

When will Achieve Life Sciences present at the H.C. Wainwright BIOCONNECT Virtual Conference?

Achieve Life Sciences will present on January 10, 2022, at 7:00 am ET.

How can investors register for the H.C. Wainwright conference featuring Achieve Life Sciences?

Investors can register for the conference by visiting the registration link provided in the press release.

What is cytisinicline, the focus of Achieve Life Sciences?

Cytisinicline is a plant-based alkaloid being developed to aid smoking cessation and treat nicotine addiction.

Is cytisinicline approved by the FDA?

No, cytisinicline is an investigational product that has not been approved by the FDA for any indication in the United States.

What health issue does Achieve Life Sciences aim to address with cytisinicline?

Achieve Life Sciences aims to tackle the global epidemic of smoking and nicotine addiction.